Neoantigen-specific CD4(+) tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

BACKGROUND: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a promising immunotherapeutic approach for patients with advanced solid tumors. While numerous advances have been made, the contribution of neoantigen-specific CD4(+)T cells within TIL infusion products remains und...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, MacLean S., Teer, Jamie K., Yu, Xiaoqing, Branthoover, Holly, Snedal, Sebastian, Rodriguez-Valentin, Madeline, Nagle, Luz, Scott, Ellen, Schachner, Ben, Innamarato, Patrick, Hall, Amy M., Blauvelt, Jamie, Rich, Carolyn J., Richards, Allison D., Ceccarelli, Jake, Langer, TJ, Yoder, Sean J., Beatty, Matthew S., Cox, Cheryl A., Messina, Jane L., Abate-Daga, Daniel, Mule, James J., Mullinax, John E., Sarnaik, Amod A., Pilon-Thomas, Shari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565316/
https://www.ncbi.nlm.nih.gov/pubmed/37802604
http://dx.doi.org/10.1136/jitc-2023-007288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565316/
https://www.ncbi.nlm.nih.gov/pubmed/37802604
http://dx.doi.org/10.1136/jitc-2023-007288

Ejemplares similares